Gilead Sciences Overview
Update this profile
Share Price
$62.83
(As of Monday Closing)
Gilead Sciences General Information
Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Contact Information
Want to dig into this profile?
We’ll help you find what you need
Learn more
Gilead Sciences Stock Performance
(As of Monday Closing)
Stock Price
Previous Close
52 wk Range
Market Cap
Shares
Average Volume
EPS
$62.83
$63.08
$57.16 - $74.12
$79.1B
1.25B
8.22M
$3.59
Gilead Sciences Financials Summary
In Thousands, USD
TTM
31-Mar-2022
FY 2021
31-Dec-2021
FY 2020
31-Dec-2020
FY 2019
31-Dec-2019
EV
94,826,535
113,029,788
78,371,550
84,073,162
Revenue
27,472,000
27,305,000
24,689,000
22,449,000
EBITDA
8,946,000
11,329,000
4,133,000
7,559,000
Net Income
4,515,000
6,225,000
123,000
5,386,000
Total Assets
63,080,000
67,952,000
68,407,000
61,627,000
Total Debt
26,208,000
26,695,000
31,402,000
24,593,000
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Gilead Sciences Valuation & Funding
Deal Type
Date
Amount
Valuation/ EBITDA
Post-Val
Status
Debt
This information is available in the PitchBook Platform. To explore Gilead Sciences‘s full profile, request access.
Request a free trial
Gilead Sciences Comparisons
Description
Primary Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portf
Pharmaceuticals
Foster City, CA
14,400
As of 2021
00.000
000000000
00.000
ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labori
000000000000000
Basel, Switzerland
000000
As of 0000
000000000000
reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaec
0000 000000000
Indianapolis, IN
00000
As of 0000
000000 - 000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trial
Gilead Sciences Competitors (23)
Company Name
Financing Status
Location
Employees
Total Raised
Last Financing Date/Type
Last Financing Amount
Novartis
Corporation
Basel, Switzerland
000000
000000000000
000 00000
Corporation
Indianapolis, IN
00000
000000 - 000
000000
Formerly VC-backed
Cambridge, MA
0000
000.00
0&0
00000
Formerly PE-Backed
Thousand Oaks, CA
00000
00.000
000000000000
00.000
0000000-00000 0000
Corporation
New York, NY
00000
00000
000000000
00000
You’re viewing 5 of 23 competitors. Get the full list »
Gilead Sciences Patents
6,222
Total Documents
Applications and Grants
000
Total Patents
Families
308
Granted
43
Pending
000
Expiring
in next 12 mo
Gilead Sciences Recent Patent Activity
Publication ID
Patent Title
Status
First Filing Date
Technology (CPC)
Citations
US-20210380561-A1
Lpa receptor antagonists and uses thereof
Pending
03-Jun-2020
0000000000
US-20210355140-A1
Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
Pending
06-May-2020
0000000000
US-20210330685-A1
Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
Pending
06-Apr-2020
000000000
US-20210309637-A1
Solid forms of a cot inhibitor compound
Pending
30-Mar-2020
0000000000
US-20210309689-A1
Methods of preparing 1'-cyano nucleosides
Pending
12-Mar-2020
C07H19/23
To view Gilead Sciences’s complete patent history, request access »
Gilead Sciences Executive Team (56)
Update this profile
Name
Title
Board Seat
Contact Info
Daniel O'Day
Chief Executive Officer, Chairman of the Board & Director
Andrew Dickinson
Chief Financial Officer, Finance & Executive Vice President
Wim Eeraerts
General Manager - Belgium & Luxemburg
Diane Wilfong
Chief Accounting Officer, Accounting & Controller, Finance
Jeremy O'Hanlon
Director, Corporate Development
You’re viewing 5 of 56 executive team members. Get the full list »
Gilead Sciences Signals
Growth Rate
0.80%
Weekly Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial
Gilead Sciences Investors
Investor Name
Investor Type
Holding
Investor Since
Participating Rounds
Contact Info
This information is available in the PitchBook Platform. To explore Gilead Sciences‘s full profile, request access.
Request a free trial
Gilead Sciences
Investments & Acquisitions (58)
Company Name
Deal Date
Deal Type
Deal Size
Industry
Lead Partner
000000 000000
23-May-2022
0000 00000
000
Drug Discovery
00000000
05-May-2022
00000 0000
0000
Other Healthcare Technology Systems
0000 0000
0000000
26-Jan-2022
00000 0000
0000
Biotechnology
0000 0000
000000 000000
27-Dec-2021
0000
0000
Biotechnology
Gritstone bio
17-Sep-2021
PIPE
0000
Biotechnology
You’re viewing 5 of 58 investments and acquisitions. Get the full list »
Gilead Sciences Exits (8)
Company Name
Exit Date
Exit Type
Exit Size
Status
Buyers
00000 000000000000
10-Aug-2021
0000
00000
Completed
000000000
17-Mar-2021
00000 00000 00
00000
Completed
00000 000000000000
17-Aug-2020
00000 00000 00
0000
Completed
000000000 00000000
01-Mar-2019
00000 00000 00
00000
Completed
Hookipa Pharma
11-Dec-2017
Later Stage VC
000.00
Completed
You’re viewing 5 of 8 exits. Get the full list »